Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Immunotherapy
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
Four separate status dimensions
- RegistryRecruiting in registry
- SiteNot verifiedUnknown, so no conclusion can be drawn.
- International accessUnknownUnknown, so no conclusion can be drawn.
- Patient matchNot assessedUnknown, so no conclusion can be drawn.
Three statuses often treated as one
A recruiting registry status does not mean a patient can immediately join this study. These three questions are answered by different parties.
Registry status
Stated by the study record owner: whether the study is listed as recruiting. It does not state whether a site is active.
Site status
Stated by the facility: whether the site is running this study now. TanyaKanker has not verified this.
International access
Stated by facility policy: whether patients from outside the local country can be accepted.
Why this appears
Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify
- • Acceptance of patients from outside the local country has not been verified.
- • We have not verified that the study site is actively running this study.
- • Eligibility is determined by the study team, not by registry data.
- • This record has never been directly verified by us.
Preliminary screening only shows overlap and data needs. Eligibility is determined by the study team.
Why this study may be relevant
- This study is recorded for Lung Cancer, the same cancer group you are exploring.
- The study requirements mention marker PD-L1, so your molecular result is relevant to discuss.
- Recorded interventions: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures.
- The study is in Phase 3 according to registry data.
- Locations are recorded in United States, Argentina, Australia.
The relevance above is assembled from registry data, not from an eligibility judgement.
Study basis
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
- Sponsor
- Merck Sharp & Dohme LLC
- Registry
- ClinicalTrials.gov NCT06170788
- Phase
- Phase 3
Cancer and markers
Recorded interventions
Study locations
- United States
Mayo Clinic in Arizona - Phoenix ( Site 0147)
Phoenix
- United States
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130)
Burbank
- United States
Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132)
Grand Junction
- United States
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
Jacksonville
- United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106)
Marietta
Showing 5 of 220 locations recorded in the registry.
What we know
- Registry status: Recruiting.
- Phase 3 with sponsor Merck Sharp & Dohme LLC.
- 220 locations recorded in the registry.
- Registry data updated 2026-10-15.
What we do not know yet
- Whether the site accepts patients from outside the local country.
- Whether the site is actively running the study now.
- Which cost components are borne by participants.
- Which documents the sponsor requires.
Main eligibility factors from the registry
- Protocol sex: all
- Protocol minimum age: 18 Years
- Complete eligibility criteria appear only in the study protocol and must be assessed by the study team.
This summary is taken from registry data. Complete criteria live in the study protocol and must be assessed by the study team.
Documents that may be needed
- Disease history summary from the treating doctor
- Most recent pathology report
- Molecular marker report if available
- Most recent imaging results
- List of current medicines
This is a general frame, not the sponsor's official list.
Updates and sources
- Registry update
- 2026-10-15
- Retrieved by TanyaKanker
- 2026-10-16
- Last verified
- Never
- Contact status
- Not contacted
Data comes from the public ClinicalTrials.gov registry of the US National Library of Medicine. Registry facts are public data; interpretation about international patient access, cost, and site readiness does NOT come from the registry and is marked unverified.
https://clinicaltrials.gov/study/NCT06170788Treatment categories
Cost
NOT VERIFIED
Not verified. The public registry does not include cost details for international patients and does not state payment coverage.
This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Other studies in a similar group
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356 | Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581 | Phase 3
Check preliminary match for your case
This screening shows overlap between your summary and the study, plus data that still needs to be completed. Eligibility remains the study team's decision.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Pembrolizumab
Drug
Reason: Uses this drug
To check
- Clinical trial document checklist
Tool
Reason: Check documents before contacting the study team
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.